Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification

Author:

Hollis Robert L.1ORCID,Meynert Alison M.2ORCID,Michie Caroline O.3,Rye Tzyvia1,Churchman Michael1ORCID,Hallas-Potts Amelia1,Croy Ian1,McCluggage W. Glenn4,Williams Alistair R.W.5ORCID,Bartos Clare1,Iida Yasushi16,Okamoto Aikou6ORCID,Dougherty Brian7,Barrett J. Carl7,March Ruth8,Matakidou Athena9ORCID,Roxburgh Patricia1011ORCID,Semple Colin A.2ORCID,Harkin D. Paul1213,Kennedy Richard1213,Herrington C. Simon1ORCID,Gourley Charlie1ORCID

Affiliation:

1. 1Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.

2. 2MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.

3. 3Edinburgh Cancer Centre, Western General Hospital, NHS Lothian, Edinburgh, UK.

4. 4Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK.

5. 5Division of Pathology, The Royal Infirmary of Edinburgh, Edinburgh, UK.

6. 6The Jikei University School of Medicine, Tokyo, Japan.

7. 7Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts.

8. 8Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK.

9. 9Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

10. 10Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Belfast, UK.

11. 11Beatson West of Scotland Cancer Centre, Glasgow, UK.

12. 12Almac Diagnostics, Craigavon, UK.

13. 13Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK.

Abstract

Abstract Purpose: High-grade serous ovarian carcinoma (HGSOC) is the most common ovarian cancer type; most patients experience disease recurrence that accumulates chemoresistance, leading to treatment failure. Genomic and transcriptomic features have been associated with differential outcome and treatment response. However, the relationship between events at the gene sequence, copy number, and gene-expression levels remains poorly defined. Experimental Design: We perform multiomic characterization of a large HGSOC cohort (n = 362) with detailed clinical annotation to interrogate the relationship between patient subgroups defined by specific molecular events. Results: BRCA2-mutant (BRCA2m) and EMSY-overexpressing cases demonstrated prolonged survival [multivariable hazard ratios (HR) 0.40 and 0.51] and significantly higher first- and second-line chemotherapy response rate. CCNE1-gained (CCNE1g) cases demonstrated underrepresentation of FIGO stage IV cases, with shorter survival but no significant difference in treatment response. We demonstrate marked overlap between the TCGA- and Tothill-derived subtypes. IMR/C2 cases displayed higher BRCA1/2m frequency (25.5%, 32.5%) and significantly greater immune cell infiltration, whereas PRO/C5 cases had the highest CCNE1g rate (23.9%, 22.2%) and were uniformly low in immune cell infiltration. The survival benefit for cases with aberrations in homologous recombination repair (HRR) genes was apparent across all transcriptomic subtypes (HR range, 0.48–0.68). There was significant co-occurrence of RB loss and HRR gene aberrations; RB loss was further associated with favorable survival within HRR-aberrant cases (multivariable HR, 0.50). Conclusions: These data paint a high-resolution picture of the molecular landscape in HGSOC, better defining patients who may benefit most from specific molecular therapeutics and highlighting those for whom novel treatment strategies are needed to improve outcomes.

Funder

MRC-funded fellowship

Target Ovarian Cancer

Tenovus Scotland

UK Medical Research Council

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3